Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
clovis oncology
Burrill Report: Financing Activity May Lift Cloud Hanging Over Biotech Industry
While biotech leaders from all over the world gathered at the 2009 BIO International Convention in Atlanta, financing activity in the sector raised hope that the cloud hanging over the industry may be lifting a little.